NCT02250443View on ClinicalTrials.gov

Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 11, 2014

Primary Completion Date

August 23, 2016

Study Completion Date

August 23, 2016

Conditions
Sporadic Inclusion Body Myositis (sIBM)
Interventions
DRUG

BYM338 (Bimagrumab)

Trial Locations (2)

85013

Novartis Investigative Site, Phoenix

02115

Novartis Investigative Site, Boston

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY